Garry E. Gold, M.D., is a clinical radiologist and an active investigator specializing in patient-oriented research. Following completion of his Master of Science in Electrical Engineering from Stanford University in 1988, Dr. Gold earned his medical degree in 1992 from the Stanford University School of Medicine. In 1993, he began the Stanford Department of Radiology Residency Program, during which he spent two years serving as an NCI Cancer Imaging Fellow from 1995-1997 under the supervision of Dr. Albert Macovski. After board certification in Radiology, Dr. Gold became an Osteoradiology Fellow at the University of California in San Diego under Dr. Donald Resnick from 1998-1999. He was appointed an Assistant Professor in Stanford’s Department of Radiology in January 2000. In 2006, Dr. Gold became an Associate Professor with tenure in the Department of Radiology. In 2011 Dr. Gold was awarded the first phase of this K24 project which has produced many successful clinically oriented researchers (see tables). In 2012, Dr. Gold was promoted to Professor of Radiology and by courtesy Bioengineering and Orthopaedic Surgery. He was also appointed as the Associate Chair for Research in Radiology at Stanford. In 2017, Dr. Gold was appointed as Vice Chair for Research and Organization in the Department.

Dr. Gold has earned an international reputation as a clinical radiologist and patient-oriented researcher specializing in osteoarthritis and translational MRI development. His unique background in electrical engineering and radiology has resulted in over 200 peer-reviewed articles and eight successful patent applications. He is Past President of the International Society for Magnetic Resonance in Medicine (ISMRM) and the Society for Computer Body Tomography and Magnetic Resonance (SCBT/MR). In recognition of his widely respected research and mentoring, he has won multiple honors, including the SCBT/MR Lauterbur Award multiple times. In 2011 he was named a Fellow of the ISMRM and Academy of Radiology Research Distinguished Investigator. In 2013 he was named Faculty of the Year for Stanford Radiology. In 2016 Dr. Gold was named as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).

Profile: https://profiles.stanford.edu/garry-gold  

Dr. Mahaffey is the Associate Dean of Clinical Research, the Vice Chair of Clinical Research in the Department of Medicine at Stanford University and the Director of the Stanford Center for Clinical Research (SCCR).  SCCR is an academic research organization to support researchers to design and conduct clinical research studies and to enroll Stanford patients in clinical trials.  Dr. Mahaffey’s own research focuses on the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. His research efforts have resulted in the approval of new FDA approved therapies for the treatment of patients with acute coronary syndromes, diabetes, and atrial fibrillation.  Dr. Mahaffey is a member of the Stanford University Institutional Review Board and has served on the IRB for 15 years.

Profile: https://profiles.stanford.edu/kenneth-mahaffey  

Profile: https://profiles.stanford.edu/oliver-aalami  

Dr. Megan Mahoney is Clinical Professor of Medicine in the Division of Primary Care and Population Health at Stanford University and Chief of Staff at Stanford Health Care. As Chief of Staff, she is honored to represent 3000 physicians at Stanford Health Care and provide oversight of medical staff clinical activities within Stanford Health Care, including quality improvement, credentialing and privileging, patient safety, and utilization management. For the last 5 years she served as chief of primary care where she led primary care precision health, practice transformation, and population health initiatives for the network of primary care faculty practices at Stanford Health Care. Before joining Stanford, she served in several leadership capacities in clinic operations, medical education and research during her decade as a faculty member at the University of California San Francisco. She was a visiting professor at Aga Khan Medical College of East Africa and was on the family medicine committee of the Kenya Ministry of Health. Dr. Mahoney specializes in innovative and transformative approaches to proactive and personalized team-based primary care that empowers patients, health care providers, and communities in the U.S. and internationally.

Profile: https://profiles.stanford.edu/megan-mahoney  

Prior to joining Stanford in 2004, Zhenan Bao was a Distinguished Member of Technical Staff in Bell Labs, Lucent Technologies. She received her Ph.D in Chemistry from the University of Chicago in 1995.  She has over 500 refereed publications and over 65 US patents with a Google Scholar H-Index >160. She pioneered a number of molecular design concepts for organic electronic materials. Her work has enabled flexible electronic circuits and displays. In the past ten years, she pioneered the field of skin-inspired organic electronic materials, which resulted in unprecedented performance or functions in medical devices, energy storage and environmental applications.

Bao is a member of the National Academy of Engineering and the National Academy of Inventors. Bao was selected as Nature’s Ten people who mattered in 2015 as a “Master of Materials” for her work on artificial electronic skin. She was awarded the inaugural ACS Central Science Disruptor and Innovator Prize in 2020, the Wilhelm Exner Medal by Austrian Federal Minister of Science 2018, ACS Award on Applied Polymer Science 2017, the L'Oréal-UNESCO For Women in Science Award in the Physical Sciences 2017, the AICHE Andreas Acrivos Award for Professional Progress in Chemical Engineering in 2014.

Profile: https://profiles.stanford.edu/zhenan-bao
Lab: http://baogroup.stanford.edu/  

Dr. Ian H. Gotlib is the David Starr Jordan Professor, Director of the Stanford Neurodevelopment, Affect, and Psychopathology (SNAP) Laboratory, and Professor of Psychology at Stanford University. From 2005-2010, Dr. Gotlib served as Senior Associate Dean for the Social Sciences, and from 2012-2018 he served as Chair of the Psychology Department.

In his research, Dr. Gotlib examines psychobiological factors that place individuals at increased risk for developing depression and engaging in suicidal behaviors, as well as processes that protect against these difficulties. More specifically, Dr. Gotlib examines neural, cognitive, social, endocrinological, and genetic factors in depressed individuals and applies findings from these investigations to the study of predictors of depression and suicidal behaviors in children at risk for this disorder. In related projects, Dr. Gotlib is also examining the differential effects of early life stress on trajectories of neurodevelopment in children through puberty in an effort to explain the increased prevalence of depression and suicidal behaviors in girls in adolescence. Finally, Dr. Gotlib is extending this work to the study of brain function and structure, endocrine function, and behaviors in neonates and infants being raised in suboptimal environments.

Dr. Gotlib’s research is supported largely by grants from the National Institutes of Health. Dr. Gotlib has received the Joseph Zubin Award for lifetime research contributions to the understanding of psychopathology, the APA Award for Distinguished Scientific Contribution, the APS Distinguished Scientist Award, and a MERIT award from NIMH.

Profile: https://profiles.stanford.edu/ian-gotlib
Lab: http://snaplab.stanford.edu/  

Dr. Mahaffey is the Associate Dean of Clinical Research, the Vice Chair of Clinical Research in the Department of Medicine at Stanford University and the Director of the Stanford Center for Clinical Research (SCCR).  SCCR is an academic research organization to support researchers to design and conduct clinical research studies and to enroll Stanford patients in clinical trials.  Dr. Mahaffey’s own research focuses on the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. His research efforts have resulted in the approval of new FDA approved therapies for the treatment of patients with acute coronary syndromes, diabetes, and atrial fibrillation.  Dr. Mahaffey is a member of the Stanford University Institutional Review Board and has served on the IRB for 15 years.

Profile: https://profiles.stanford.edu/kenneth-mahaffey  

Prior to joining Stanford in 2004, Zhenan Bao was a Distinguished Member of Technical Staff in Bell Labs, Lucent Technologies. She received her Ph.D in Chemistry from the University of Chicago in 1995.  She has over 500 refereed publications and over 65 US patents with a Google Scholar H-Index >160. She pioneered a number of molecular design concepts for organic electronic materials. Her work has enabled flexible electronic circuits and displays. In the past ten years, she pioneered the field of skin-inspired organic electronic materials, which resulted in unprecedented performance or functions in medical devices, energy storage and environmental applications.

Bao is a member of the National Academy of Engineering and the National Academy of Inventors. Bao was selected as Nature’s Ten people who mattered in 2015 as a “Master of Materials” for her work on artificial electronic skin. She was awarded the inaugural ACS Central Science Disruptor and Innovator Prize in 2020, the Wilhelm Exner Medal by Austrian Federal Minister of Science 2018, ACS Award on Applied Polymer Science 2017, the L'Oréal-UNESCO For Women in Science Award in the Physical Sciences 2017, the AICHE Andreas Acrivos Award for Professional Progress in Chemical Engineering in 2014.

Profile: https://profiles.stanford.edu/zhenan-bao
Lab: http://baogroup.stanford.edu/  

DeSimone joined Stanford after a 30-year career at the University of North Carolina. He has made significant breakthroughs in green chemistry, medical devices, nanotechnology and 3D printing.  He has authored >370 publications (42,000 citations) and is an inventor on >200 patents.  He has co-founded several companies including Liquidia (NASDAQ: LQDA) and Carbon.  DeSimone received the Presidential Green Chemistry Challenge Award, Heinz Award, Lemelson-MIT Prize, 2019 EY Entrepreneur of the Year Award and National Medal of Technology and Innovation.  He is one of only 25 individuals elected to all three U.S. National Academies—the National Academy of Sciences, Medicine, and Engineering.

Profile: https://profiles.stanford.edu/joseph-desimone  

DeSimone joined Stanford after a 30-year career at the University of North Carolina. He has made significant breakthroughs in green chemistry, medical devices, nanotechnology and 3D printing.  He has authored >370 publications (42,000 citations) and is an inventor on >200 patents.  He has co-founded several companies including Liquidia (NASDAQ: LQDA) and Carbon.  DeSimone received the Presidential Green Chemistry Challenge Award, Heinz Award, Lemelson-MIT Prize, 2019 EY Entrepreneur of the Year Award and National Medal of Technology and Innovation.  He is one of only 25 individuals elected to all three U.S. National Academies—the National Academy of Sciences, Medicine, and Engineering.

Profile: https://profiles.stanford.edu/joseph-desimone  

Dr. Bustamante is an internationally recognized leader in the application of data science and genomics technology to problems in medicine, agriculture, and biology. He received his PhD in Biology and MS in Statistics from Harvard University (2001), was on the faculty at Cornell University (2002-9), and was named a MacArthur Fellow in 2010. Dr. Bustamante was the inaugural chair of and is currently professor of Biomedical Data Science, as well as Genetics, and (by courtesy) Biology at Stanford University. Dr. Bustamante has a passion for building new academic units, non-profits, and companies to solve pressing scientific challenges. He is founding director of the Stanford Center for Computational, Evolutionary, and Human Genomics (CEHG). He is a co-founder of ARC Bio, Liberty Biosecurity, and EdenRoc Sciences where he is on the Board of Directors. He advised the founding teams of InVitae, Personalis, FaunaBio, Embark Vet, Etalon DX, Imprimed, and GenomeLink. He currently serves as a venture partner at Fidelity’s early stage biotech and pharma fund, F Prime Capital. 

Profile: https://med.stanford.edu/profiles/carlos-bustamante
Lab: https://bustamantelab.stanford.edu/  

Dr. Langlotz is Professor of Radiology and Biomedical Informatics and Director of the Center for Artificial Intelligence in Medicine and Imaging (AIMI Center) at Stanford University, which supports outstanding interdisciplinary artificial intelligence research that optimizes how clinical images are used to promote health.  He is also responsible for the computer technology that supports the Stanford Radiology practice.

As a graduate student in computer science, Dr. Langlotz was a member of the team that implemented the first AI system in clinical practice.  He has led many national and international efforts to improve radiology, including the RadLex™ terminology standard, the RadLex™ Playbook of radiology exam codes, the RSNA report template library, a technical standard for communication of radiology report templates, and a national COVID-19 research imaging repository. He has published over 100 scholarly articles, and is author of the 2015 book “The Radiology Report: A Guide to Thoughtful Communication for Radiologists and Other Medical Professionals”.

Raised in St. Paul, Minnesota, Dr. Langlotz received his undergraduate degree in Human Biology, masters in Computer Science, MD in Medicine, and PhD in Medical Information Science, all from Stanford University. He currently serves on the Board of Directors of the Radiological Society of North America (RSNA) as Liaison for Information Technology. He has founded three healthcare information technology companies, most recently Montage Healthcare Solutions, which was acquired by Nuance Communications in 2016.

Profile: https://profiles.stanford.edu/curtis-langlotz

Dr. Demirci is currently a Professor with tenure at Stanford University School of Medicine and Principal Investigator of the Demirci Bio-Acoustic MEMS in Medicine (BAMM) Lab at the Canary Center at Stanford for Cancer Early Detection. He received his B.S. degree in Electrical Engineering in 1999 as a James B. Angell Scholar (summa cum laude) from University of Michigan, Ann Arbor. He received his M.S. degree in 2001 in Electrical Engineering, M.S. degree in Management Science and Engineering in 2005, and Ph.D. in Electrical Engineering in 2005, all from Stanford University.

BAMM Lab specializes in applying micro- and nanoscale technologies to problems in medicine and early cancer detection at the interface between micro/nanoscale engineering and medicine. Our goal is to apply innovative technologies to clinical problems. Our major research theme focuses on creating new microfluidic technology platforms targeting broad applications in medicine. In this interdisciplinary space at the convergence of engineering, biology and materials science, we create novel technologies for disposable point-of-care (POC) diagnostics and monitoring of infectious diseases, cancer and controlling cellular microenvironment in nanoliter droplets for biopreservation and microscale tissue engineering applications. These applications are unified around our expertise to test the limits of cell manipulation by establishing microfluidic platforms to provide solutions to real world problems at the clinic.

Our lab creates technologies to manipulate cells in nanoliter volumes to enable solutions for real world problems in medicine including applications in infectious disease diagnostics and monitoring for global health, cancer early detection, cell encapsulation in nanoliter droplets for cryobiology, and bottom-up tissue engineering. Dr. Demirci has published over 120 peer reviewed publications in journals including PNAS, Nature Communications, Advanced Materials, Small, Trends in Biotechnology, Chemical Society Reviews and Lab-chip, over 150 conference abstracts and proceedings, 10+ book chapters, and an edited book. His work was highlighted in Wired Magazine, Nature Photonics, Nature Medicine, MIT Technology Review, Reuters Health News, Science Daily, AIP News, BioTechniques, and Biophotonics. He is fellow-elect of the American Institute of Biological and Medical Engineering (AIMBE, 2017). His scientific work has been recognized by numerous national and international awards including the NSF Faculty Early Career Development (CAREER) Award (2012), the IEEE-EMBS Early Career Achievement Award (2012), Scientist of the year award from Stanford radiology Department (2017). He was selected as one of the world’s top 35 young innovators under the age of 35 (TR-35) by the MIT Technology Review at the age of 28. In 2004, he led a team that won the Stanford University Entrepreneur’s Challenge Competition and Global Start-up Competition in Singapore. His work has been translated to start-up companies including DxNow, KOEK Biotechnology and LEVITAS. There has been over 10,000 live births in the US, Europe, Asia, and Middle East using the sperm selection technology that came out of Dr. Demirci's lab.

Profile: https://profiles.stanford.edu/utkan-demirci
Lab: https://bammlabs.stanford.edu/  

Harmeet Bedi is an Interventional Pulmonologist and Clinical Assistant Professor at Stanford University Medical Center and School of Medicine. His expertise is in minimally invasive techniques used in the diagnosis and treatment of various airway and lung diseases such as lung cancer, benign and malignant airway obstruction, and pleural diseases. His research interests revolve around novel bronchoscopic technologies, lung nodule diagnosis, and lung transplant-related airway complications.

Profile: https://profiles.stanford.edu/harmeet-bedi

Dr. Fan studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical studies. Based on preclinical findings, she has initiated clinical trials studying how tyrosine kinase inhibitors impact the hypoxia pathway in kidney cancer and the use of atorvastatin for the treatment of patients with certain non-Hodgkin's lymphomas. In the laboratory, she also uses preclinical models of cancer to validate new nanotechnology strategies for tumor diagnosis and treatment. She has shown that a new nano-immunoassay (NIA) can be used to measure how well drugs work in tumor cells sampled from individual patients with leukemia, lymphoma and myelodysplastic syndrome taking novel targeted therapies (Fan et al. Nature Medicine 2009, Seetharam, Fan et al. Leukemia Research 2012, Fan et al Oncotarget 2012). She is currently expanding her translational research to include early diagnostics, therapeutic monitoring, and prediction of response to therapeutics in solid tumors such as kidney cancer and lung cancer, with the goal of helping to make personalized medicine possible.

Profile: https://profiles.stanford.edu/alice-fan

With my background in medicine, microdevice engineering, and nanotechnology, my strengths lie in developing novel solutions to urgent problems in medicine and cancer research. Having developed a diagnostic microfluidic device at Caltech and initiated a clinical trial to test the device on glioblastoma patients at UCLA, I’m particularly interested in moving promising technologies past the proof-of-concept phase and into the clinic. My career goals are to continue to work at the interface of medicine and technology as an academic scientist, engineering new wearable and implantable technologies for earlier cancer detection and continuous monitoring.

Profile: https://profiles.stanford.edu/ophir-vermesh

Dr. Ying Chang is an Adjunct Professor of the Department of Chemical Engineering, an affiliate member of Precision Health and Integrated Diagnostic Center of the School of Medicine, and a Co-Director of the Taiwan-Stanford Partnership program, LEAP, at Stanford University. She is also a Research Fellow at the Genomics Research Center, Academia Sinica, and an Adjunct Professor at the Center of Liquid Biopsy at Kaohsiung Medical University, Taiwan. Formerly, she was an Assistant Professor in the Department of Chemical Engineering and Materials Science, and the Department of Biomedical Engineering at the University of California-Irvine, Irvine, CA. Prior to her academic appointments, Dr. Chang had worked in various industrial R&D laboratories including as a Senior Engineer for the hard drive media at Maxmedia California, San Jose, CA (now Seagate), a Postdoctoral Scientist for the materials design of GeneChip at Affymetrix Corp, Santa Clara, CA (now Thermal Fisher Scientific). Her recent invention in circulating tumor cells platform has led to a startup company, Cellmax Life in 2013. Highlights of her research include integrated nanomaterials, microfluidics, and bioreactors to control stem cell fates for tissue engineering and liquid biopsy for cancer diagnostics and precision medicine. Dr. Chang received her BS from National Taiwan University and PhD from Stanford University in Chemical Engineering.’

Administrative Appointments
Co-Director, Taiwan LEAP@Stanford Program (2017 - Present)

Research Interests
Biomimetic Smart Materials and Interfaces
Rare Cell Isolation, Purification and Maintenance by Smart Surfaces and Microfluidics

Profile: https://profiles.stanford.edu/ying-chih-chang  

Dr. Joel Dudley serves as the Chief Scientific Officer at Tempus. Dr. Dudley was Associate Professor of Genetics and Genomic Sciences and founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. He also served as Executive Vice President for Precision Health for the Mount Sinai Health System. Prior to Mount Sinai, he held positions as co-founder of NuMedii, Inc. developing machine learning technologies for drug discovery and Consulting Professor of Systems Medicine in the Department of Pediatrics at Stanford University School of Medicine. His more than 200 peer-reviewed research publications established novel precision medicine paradigms at the nexus of -omics, digital health, artificial intelligence (AI), scientific wellness, and healthcare delivery. His work has been featured in the New York Times, Wall Street Journal, Scientific American, MIT Technology Review, CNBC, and other popular media outlets. He was named in 2014 as one of the 100 most creative people in business by Fast Company magazine. He is co-author of the book Exploring Personal Genomics from Oxford University Press. Dr. Dudley received a BS in Microbiology from Arizona State University and an MS and PhD in Biomedical Informatics from Stanford University School of Medicine.

Profile: https://www.tempus.com/team_members/joel-dudley-phd/